We are live on
!
Find out more
VC
Vivo Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
911.44%
This Fund
S&P 500
This Quarter
Est. Return
+19.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$755M
AUM Growth
-$138M
(-15%)
Cap. Flow
-$136M
Cap. Flow
% of AUM
-17.97%
Top 10 Holdings %
Top 10 Hldgs %
75.28%
Holding
43
New
3
Increased
4
Reduced
7
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$8.53M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$7.02M |
| 3 |
CMPS
Compass Pathways
CMPS
|
+$6.74M |
| 4 |
ETNB
89bio
ETNB
|
+$3.29M |
| 5 |
Surrozen
SRZN
|
+$3.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$89.3M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$50.6M |
| 3 |
Delcath Systems
DCTH
|
+$13.6M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
+$3.04M |
| 5 |
Rezolute
RZLT
|
+$2.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cogent Biosciences
COGT
$7.22B
| $6.72M | 0.89% |
1,122,471
| – | – |
|
27
Unicycive Therapeutics
UNCY
$143M
| $6.54M | 0.87% |
1,137,015
+140,000
| +14% | +$854K |
|
28
Celcuity
CELC
$4.53B
| $6.17M | 0.82% |
610,500
| – | – |
|
|
29
Rezolute
RZLT
$451M
| $6.13M | 0.81% |
2,112,432
-685,272
| -24% | -$2.98M |
|
30
Sera Prognostics
SERA
$78.3M
| $6.07M | 0.8% |
1,650,440
| – | – |
|
31
Olema Pharmaceuticals
OLMA
$1.01B
| $5.66M | 0.75% |
1,505,862
| – | – |
|
|
RGLS
32
DELISTED
Regulus Therapeutics
RGLS
| $4.72M | 0.62% |
2,696,426
-2,303,574
| -46% | -$3.04M |
|
|
SLN
33
Silence Therapeutics
SLN
$531M
| $3.12M | 0.41% |
1,105,454
| – | – |
|
|
34
Surrozen
SRZN
$255M
| $3.03M | 0.4% |
+260,000
| New | +$3.02M |
|
|
ETNB
35
DELISTED
89bio
ETNB
| $2.74M | 0.36% |
+376,804
| New | +$3.29M |
|
36
Bolt Biotherapeutics
BOLT
$7.59M
| $1.41M | 0.19% |
176,065
| – | – |
|
37
Tenax Therapeutics
TENX
$488M
| $1.36M | 0.18% |
208,333
| – | – |
|
|
ALLK
38
DELISTED
Allakos
ALLK
| $174K | 0.02% |
765,500
-2,190,610
| -74% | -$989K |
|
39
Aligos Therapeutics
ALGS
$29.3M
| $84.1K | 0.01% |
10,199
-131,680
| -93% | -$2.89M |
|
40
Precision BioSciences
DTIL
$193M
| $22.3K | ﹤0.01% |
4,675
| – | – |
|
41
Corbus Pharmaceuticals
CRBP
$177M
| – | – |
-166,794
| Closed | -$1.97M |
|
|
DBVT
42
DBV Technologies
DBVT
$843M
| – | – |
-32,020
| Closed | -$98.9K |
|
43
Q32 Bio
QTTB
$491M
| – | – |
-20,559
| Closed | -$70.7K |
|
Similar funds
FCCPG
AIM
SC
MB
CCM
TIM
CS
KOC
Vivo Capital's Q1 2025 Portfolio in Review
As of Q1 2025, Vivo Capital held 43 positions worth $755M, down 15% from $893M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Vivo Capital withdrew a net $136M in Q1 2025, closing 3 positions and reducing 7 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $1.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Vivo Capital opened a new position in Akero Therapeutics worth $8.14M.
- Vivo Capital's largest Q1 2025 buy was Akero Therapeutics: 201,168 shares worth $8.14M.
- Vivo Capital added most to Oric Pharmaceuticals in Q1 2025, an estimated $7.02M increase.
- Vivo Capital's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $89.3M.
- Vivo Capital fully exited Corbus Pharmaceuticals in Q1 2025, selling an estimated $1.97M.
- Vivo Capital's ten largest holdings make up 75% of its $755M portfolio in Q1 2025.
- Vivo Capital opened 3 new positions and closed 3 in Q1 2025.
- Vivo Capital's portfolio value fell 15% quarter-over-quarter to $755M.
Based on Vivo Capital's 13F filing for Q1 2025, filed 12 May 2025.